Molecular Mechanisms of Schizophrenia

Schizophrenia is a complex disorder, where family, twin and adoption studies have been demonstrating a high heritability of the disease and that this disease is not simply defined by several major genes but rather evolves from addition or potentiation of a specific cluster of genes, which subsequently determines the genetic vulnerability of an individual. Linkage and association studies suggest that a genetic vulnerablility, is not forcefully leading to the disease since triggering factors and environmental influences, i.e. birth complications, drug abuse, urban background or time of birth have been identified. This has lead to the assumption that schizophrenia is not only a genetically defined static disorder but a dynamic process leading to dysregulation of multiple pathways. There are several different hypothesis based on several facets of the disease, some of them due to the relatively well-known mechanisms of therapeutic agents. The most widely considered neurodevelopmental hypothesis of schizophrenia integrates environmental influences and causative genes. The dopamine hypothesis of schizophrenia is based on the fact that all common treatments involve antidopaminergic mechanisms and genes such as DRD2, DRD3, DARPP-32, BDNF or COMT are closely related to dopaminergic system functioning. The glutamatergic hypothesis of schizophrenia lead recently to a first successful mGlu2/3 receptor agonistic drug and is underpinned by significant findings in genes regulating the glutamatergic system (SLC1A6, SLC1A2 GRIN1, GRIN2A, GRIA1, NRG1, ErbB4, DTNBP1, DAAO, G72/30, GRM3). Correspondingly, GABA has been proposed to modulate the pathophysiology of the disease which is represented by the involvement of genes like GABRA1, GABRP, GABRA6 and Reelin. Moreover, several genes implicating immune, signaling and networking deficits have been reported to be involved in the disease, i.e. DISC1, RGS4, PRODH, DGCR6, ZDHHC8, DGCR2, Akt, CREB, IL-1B, IL-1RN, IL-10, IL-1B. However, molecular findings suggest that a complex interplay between receptors, kinases, proteins and hormones is involved in schizophrenia. In a unifying hypothesis, different cascades merge into another that ultimately lead to the development of symptoms adherent to schizophrenic disorders.

[1]  N. Rajakumar,et al.  Antipsychotics alter the protein expression levels of β-catenin and GSK-3 in the rat medial prefrontal cortex and striatum , 2005, Biological Psychiatry.

[2]  Manuel Desco,et al.  Ventricular enlargement in schizophrenia is associated with a genetic polymorphism at the interleukin-1 receptor antagonist gene , 2005, NeuroImage.

[3]  P. Ascher,et al.  Glycine potentiates the NMDA response in cultured mouse brain neurons , 1987, Nature.

[4]  E. Gershon,et al.  Meta-analysis of whole-genome linkage scans of bipolar disorder and schizophrenia , 2002, Molecular Psychiatry.

[5]  Y. Fukumaki,et al.  Association study of polymorphisms in the excitatory amino acid transporter 2 gene (SLC1A2) with schizophrenia , 2004, BMC psychiatry.

[6]  D. Lewis,et al.  Disease-specific changes in regulator of G-protein signaling 4 (RGS4) expression in schizophrenia , 2001, Molecular Psychiatry.

[7]  P. Falkai,et al.  [Advances in neurobiological understanding of schizophrenia. Perspectives for new therapeutic concepts]. , 2006, Der Nervenarzt.

[8]  S. Akbarian,et al.  Molecular and cellular mechanisms of altered GAD1/GAD67 expression in schizophrenia and related disorders , 2006, Brain Research Reviews.

[9]  P. Levitt,et al.  Linkage disequilibrium patterns and functional analysis of RGS4 polymorphisms in relation to schizophrenia. , 2007, Schizophrenia bulletin.

[10]  M. Tohyama,et al.  DISC1 localizes to the centrosome by binding to kendrin. , 2004, Biochemical and biophysical research communications.

[11]  Robin M. Murray,et al.  Environmental risk factors for psychosis , 2005, Dialogues in clinical neuroscience.

[12]  Yuhei Nakamura,et al.  Functional polymorphism of −141C Ins/Del in the dopamine D2 receptor gene promoter and schizophrenia , 1998, Psychiatry Research.

[13]  Thomas E. Nichols,et al.  Impact of complex genetic variation in COMT on human brain function , 2006, Molecular Psychiatry.

[14]  Benjamin W. H. Lim,et al.  Regulation of the GABA cell phenotype in hippocampus of schizophrenics and bipolars , 2007, Proceedings of the National Academy of Sciences.

[15]  J. Vázquez-Barquero,et al.  Association between the interleukin‐1 receptor antagonist gene and negative symptom improvement during antipsychotic treatment † , 2006, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[16]  R. Yolken,et al.  Antibodies to Toxoplasma gondii in patients with schizophrenia: a meta-analysis. , 2007, Schizophrenia bulletin.

[17]  Daniel R Weinberger,et al.  Human dysbindin (DTNBP1) gene expression in normal brain and in schizophrenic prefrontal cortex and midbrain. , 2004, Archives of general psychiatry.

[18]  David J. Porteous,et al.  The Genetics and Biology of Disc1—An Emerging Role in Psychosis and Cognition , 2006, Biological Psychiatry.

[19]  Daniel R. Weinberger,et al.  Evidence for statistical epistasis between catechol-O-methyltransferase (COMT) and polymorphisms in RGS4, G72 (DAOA), GRM3, and DISC1: influence on risk of schizophrenia , 2007, Human Genetics.

[20]  M. Krebs,et al.  Age at onset of schizophrenia: interaction between brain-derived neurotrophic factor and dopamine D3 receptor gene variants , 2005, Neuroreport.

[21]  S. Snyder,et al.  Disrupted-in-Schizophrenia-1 (DISC-1): Mutant truncation prevents binding to NudE-like (NUDEL) and inhibits neurite outgrowth , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[22]  D. Collier,et al.  Evaluation of a Susceptibility Gene for Schizophrenia: Genotype Based Meta-Analysis of RGS4 Polymorphisms from Thirteen Independent Samples , 2006, Biological Psychiatry.

[23]  M. Schwarz,et al.  Schizophrenia as an inflammation-mediated dysbalance of glutamatergic neurotransmission , 2006, Neurotoxicity Research.

[24]  Vicki L. Ellingrod,et al.  Association between the polymorphic GRM3 gene and negative symptom improvement during olanzapine treatment , 2005, Schizophrenia Research.

[25]  S. Akhondzadeh,et al.  Celecoxib as adjunctive therapy in schizophrenia: A double-blind, randomized and placebo-controlled trial , 2007, Schizophrenia Research.

[26]  A. Chakravarti,et al.  No evidence for association to the G72/G30 locus in an independent sample of schizophrenia families , 2005, Molecular Psychiatry.

[27]  S. Magder,et al.  Estrogen induced changes in Akt-dependent activation of endothelial nitric oxide synthase and vasodilation , 2004, Steroids.

[28]  J. Shields,et al.  A polygenic theory of schizophrenia. , 1972, Proceedings of the National Academy of Sciences of the United States of America.

[29]  M. R. Sargolzaee,et al.  Association of AKT1 haplotype with the risk of schizophrenia in Iranian population , 2006, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[30]  T. d'Amato,et al.  No major role for the dopamine D2 receptor Ser → Cys311 mutation in schizophrenia , 1994, Psychiatric genetics.

[31]  Karin E. Borgmann-Winter,et al.  Altered neuregulin 1–erbB4 signaling contributes to NMDA> receptor hypofunction in schizophrenia , 2006, Nature Medicine.

[32]  P. Sham,et al.  Genetic and physiological data implicating the new human gene G72 and the gene for d-amino acid oxidase in schizophrenia , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[33]  M. Owen,et al.  No evidence for association between polymorphisms in GRM3 and schizophrenia , 2005, BMC psychiatry.

[34]  Christoph Schmitz,et al.  Gene regulation by hypoxia and the neurodevelopmental origin of schizophrenia , 2006, Schizophrenia Research.

[35]  E. Hirsch,et al.  Phosphoinositide 3-kinases as a common platform for multi-hormone signaling. , 2007, The Journal of endocrinology.

[36]  Teresa Tallerico,et al.  Dopamine D2 receptor promoter polymorphism: no association with schizophrenia , 1999, Psychiatry Research.

[37]  P. Gorwood,et al.  Association and excess of transmission of a DRD2 haplotype in a sample of French schizophrenic patients. , 2001, Schizophrenia Research.

[38]  R. Kessler,et al.  Lifetime prevalence, demographic risk factors, and diagnostic validity of nonaffective psychosis as assessed in a US community sample. The National Comorbidity Survey. , 1996, Archives of general psychiatry.

[39]  D. Javitt,et al.  Comparative effects of glycine and d-cycloserine on persistent negative symptoms in schizophrenia: a retrospective analysis , 2004, Schizophrenia Research.

[40]  S. Cichon,et al.  Metabotropic glutamate receptor 3 (GRM3) gene variation is not associated with schizophrenia or bipolar affective disorder in the German population. , 2002, American journal of medical genetics.

[41]  M. Munafo,et al.  Lack of association of the COMT (Val158/108 Met) gene and schizophrenia: a meta-analysis of case–control studies , 2005, Molecular Psychiatry.

[42]  J. Rain,et al.  Disrupted in Schizophrenia 1 and Nudel form a neurodevelopmentally regulated protein complex: implications for schizophrenia and other major neurological disorders , 2004, Molecular and Cellular Neuroscience.

[43]  P. Sullivan,et al.  Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies. , 2003, Archives of general psychiatry.

[44]  S. Faraone,et al.  No association of G72 and d-amino acid oxidase genes with schizophrenia , 2006, Schizophrenia Research.

[45]  M. King,et al.  Schizophrenia: a common disease caused by multiple rare alleles , 2007, British Journal of Psychiatry.

[46]  Paul J. Harrison The neuropathology of schizophrenia , 2008 .

[47]  Alan S. Brown,et al.  Prenatal infection as a risk factor for schizophrenia. , 2006, Schizophrenia bulletin.

[48]  S H Snyder,et al.  Serine racemase: a glial enzyme synthesizing D-serine to regulate glutamate-N-methyl-D-aspartate neurotransmission. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[49]  A. Malhotra,et al.  COMT genotype increases risk for bipolar I disorder and influences neurocognitive performance. , 2007, Bipolar disorders.

[50]  Paul Greengard,et al.  Evidence for decreased DARPP-32 in the prefrontal cortex of patients with schizophrenia. , 2002, Archives of general psychiatry.

[51]  N. Brandon,et al.  DISC1 and DISC2: discovering and dissecting molecular mechanisms underlying psychiatric illness , 2004, Annals of medicine.

[52]  P. Riederer,et al.  Insertion/deletion variant (−141C Ins/Del) in the 5′ regulatory region of the dopamine D2 receptor gene: lack of association with schizophrenia and bipolar affective disorder , 1998, Journal of Neural Transmission.

[53]  C. Crombie,et al.  Association analysis of the RGS4 gene in Han Chinese and Scottish populations with schizophrenia , 2005, Genes, brain, and behavior.

[54]  Ann-Christine Ehlis,et al.  Impact of Catechol-O-Methyltransferase on Prefrontal Brain Functioning in Schizophrenia Spectrum Disorders , 2007, Neuropsychopharmacology.

[55]  N. Brandon,et al.  Expression of disrupted in schizophrenia 1 (DISC1) protein in the adult and developing mouse brain indicates its role in neurodevelopment , 2004, Molecular Psychiatry.

[56]  P. Insel,et al.  Multi-tasking RGS proteins in the heart: the next therapeutic target? , 2005, Circulation research.

[57]  R. Belmaker,et al.  Low GSK-3 activity in frontal cortex of schizophrenic patients , 2001, Schizophrenia Research.

[58]  Lin He,et al.  Significant Association Between the Genetic Variations in the 5′ End of the N-Methyl-D-Aspartate Receptor Subunit Gene GRIN1 and Schizophrenia , 2006, Biological Psychiatry.

[59]  A. Shulgin 3-Methoxy-4 5-methylenedioxy Amphetamine, a New Psychotomimetic Agent , 1964, Nature.

[60]  P. Schofield,et al.  Heterozygous neuregulin 1 mice are more sensitive to the behavioural effects of Δ9-tetrahydrocannabinol , 2007, Psychopharmacology.

[61]  G. Kirov,et al.  Evidence that interaction between neuregulin 1 and its receptor erbB4 increases susceptibility to schizophrenia , 2006, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[62]  H. Möller,et al.  IL-2 and IL-4 polymorphisms as candidate genes in schizophrenia , 2006, European Archives of Psychiatry and Clinical Neuroscience.

[63]  K. Bechter Die milde Enzephalitishypothese - neue Befunde und Studien , 2004 .

[64]  R. Anney,et al.  Association between dopamine D3 receptor gene polymorphisms and schizophrenia in an isolate population , 2005, Schizophrenia Research.

[65]  D. Weinberger,et al.  Cell biology of the hippocampal formation in schizophrenia , 1999, Biological Psychiatry.

[66]  D. Lancet,et al.  Is the G72/G30 locus associated with schizophrenia? single nucleotide polymorphisms, haplotypes, and gene expression analysis , 2004, Biological Psychiatry.

[67]  J. Hoenicka,et al.  C957T DRD2 polymorphism is associated with schizophrenia in Spanish patients , 2006, Acta psychiatrica Scandinavica.

[68]  Chang-Gyu Hahn,et al.  Dysbindin-1 is a synaptic and microtubular protein that binds brain snapin. , 2006, Human molecular genetics.

[69]  Douglas W. Jones,et al.  P300 and genetic risk for schizophrenia. , 2003, Archives of general psychiatry.

[70]  C. P. Morris,et al.  The C/C genotype of the C957T polymorphism of the dopamine D2 receptor is associated with schizophrenia , 2005, Schizophrenia Research.

[71]  M. Schwarz,et al.  Decreased levels of soluble intercellular adhesion Molecule-1 (sICAM-1) in unmedicated and medicated schizophrenic patients , 2000, Biological Psychiatry.

[72]  E. Tan,et al.  Polymorphisms of dopamine receptors and tardive dyskinesia among Chinese patients with schizophrenia , 2003, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[73]  D StClair,et al.  -141 C del/ins polymorphism of the dopamine receptor 2 gene is associated with schizophrenia in a British population. , 1999, American journal of medical genetics.

[74]  Stephan Eliez,et al.  Risk factors for the emergence of psychotic disorders in adolescents with 22q11.2 deletion syndrome. , 2007, The American journal of psychiatry.

[75]  M. Owen,et al.  Is COMT a susceptibility gene for schizophrenia? , 2007, Schizophrenia bulletin.

[76]  Laurent Gouya,et al.  The 3′ region of the DRD2 gene is involved in genetic susceptibility to schizophrenia , 2004, Schizophrenia Research.

[77]  O. Guillin,et al.  Brain-derived neurotrophic factor in schizophrenia and its relation with dopamine. , 2007, International review of neurobiology.

[78]  Paul Greengard,et al.  DARPP-32 mediates the actions of multiple drugs of abuse , 2005, The AAPS Journal.

[79]  M. Owen,et al.  Association analysis of AKT1 and schizophrenia in a UK case control sample , 2007, Schizophrenia Research.

[80]  R. Conley,et al.  Synaptic differences in the patch matrix compartments of subjects with schizophrenia: A postmortem ultrastructural study of the striatum , 2005, Neurobiology of Disease.

[81]  S. Kapur,et al.  Schizophrenia: more dopamine, more D2 receptors. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[82]  P. Schlattmann,et al.  Association of the G1947A COMT (Val108/158Met) gene polymorphism with prefrontal P300 during information processing , 2003, Biological Psychiatry.

[83]  L. Heston,et al.  Failure to confirm association between RGS4 haplotypes and schizophrenia in Caucasians , 2005, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[84]  Jeffrey A Lieberman,et al.  Recent advances in the neurobiology of schizophrenia. , 2003, Molecular interventions.

[85]  M. Leboyer,et al.  Schizotypal dimensions: An intermediate phenotype associated with the COMT high activity allele , 2007, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[86]  M. Karayiorgou,et al.  The molecular genetics of the 22q11-associated schizophrenia. , 2004, Brain research. Molecular brain research.

[87]  Jürgen Gallinat,et al.  Genetic Variations of the NR3A Subunit of the NMDA Receptor Modulate Prefrontal Cerebral Activity in Humans , 2007, Journal of Cognitive Neuroscience.

[88]  John Stewart,et al.  A genome-wide scan for linkage to chromosomal regions in 382 sibling pairs with schizophrenia or schizoaffective disorder. , 2002, The American journal of psychiatry.

[89]  M. Itokawa,et al.  Association of dopamine D2 receptor molecular variant with schizophrenia , 1994, The Lancet.

[90]  G. Racagni,et al.  Association Study of –1727 A/T, –50 C/T and (CAA)n Repeat GSK-3β Gene Polymorphisms with Schizophrenia , 2004, Neuropsychobiology.

[91]  A. Mortimer,et al.  Relationship between estrogen and schizophrenia , 2007, Expert review of neurotherapeutics.

[92]  K. Någren,et al.  C957T polymorphism of the dopamine D2 receptor (DRD2) gene affects striatal DRD2 availability in vivo , 2004, Molecular Psychiatry.

[93]  Takahisa Taguchi,et al.  Evidence of novel neuronal functions of dysbindin, a susceptibility gene for schizophrenia. , 2004, Human molecular genetics.

[94]  P. DeRosse,et al.  Disrupted in Schizophrenia 1 Genotype and Positive Symptoms in Schizophrenia , 2007, Biological Psychiatry.

[95]  M C O'Donovan,et al.  The molecular genetics of schizophrenia: new findings promise new insights , 2004, Molecular Psychiatry.

[96]  R. Panizzutti,et al.  Cofactors of serine racemase that physiologically stimulate the synthesis of the N-methyl-d-aspartate (NMDA) receptor coagonist d-serine , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[97]  Christopher P Austin,et al.  DISC1 (Disrupted-In-Schizophrenia 1) is a centrosome-associated protein that interacts with MAP1A, MIPT3, ATF4/5 and NUDEL: regulation and loss of interaction with mutation. , 2003, Human molecular genetics.

[98]  Mark Millan Le récepteur dopaminergique D3 : nouvelle cible pour un traitement amélioré de la schizophrénie , 2005 .

[99]  Leena Peltonen,et al.  Genome scan meta-analysis of schizophrenia and bipolar disorder, part II: Schizophrenia. , 2003, American journal of human genetics.

[100]  R. Straub,et al.  Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[101]  Hans O Kalkman,et al.  The role of the phosphatidylinositide 3-kinase-protein kinase B pathway in schizophrenia. , 2006, Pharmacology & therapeutics.

[102]  P. Iatropoulos,et al.  Glutamate AMPA receptor subunit 1 gene (GRIA1) and DSM‐IV‐TR schizophrenia: A pilot case‐control association study in an Italian sample , 2006, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[103]  O. Pietiläinen,et al.  The role of DTNBP1, NRG1, and AKT1 in the genetics of schizophrenia in Finland , 2007, Schizophrenia Research.

[104]  M. Karayiorgou,et al.  Convergent evidence for impaired AKT1-GSK3β signaling in schizophrenia , 2004, Nature Genetics.

[105]  Y. Fukumaki,et al.  Association study of polymorphisms in the glutamate transporter genes SLC1A1, SLC1A3, and SLC1A6 with schizophrenia , 2007, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[106]  K. Hashimoto,et al.  Identification of Multiple Serine Racemase (SRR) mRNA Isoforms and Genetic Analyses of SRR and DAO in Schizophrenia and d-Serine Levels , 2005, Biological Psychiatry.

[107]  R. Straub,et al.  Expression of DISC 1 binding partners is reduced in schizophrenia and associated with DISC 1 SNPs , 2006 .

[108]  A. Tuulio-Henriksson,et al.  Families with the risk allele of DISC1 reveal a link between schizophrenia and another component of the same molecular pathway, NDE1. , 2007, Human molecular genetics.

[109]  J. Krystal,et al.  Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. , 1994, Archives of general psychiatry.

[110]  J. Duan,et al.  Haplotypic association spanning the 22q11.21 genes COMT and ARVCF with schizophrenia , 2005, Molecular Psychiatry.

[111]  Alan S. Brown,et al.  Prenatal exposure to maternal genital and reproductive infections and adult schizophrenia. , 2006, The American journal of psychiatry.

[112]  Chen-Hao Li,et al.  Mutation analysis of DARPP-32 as a candidate gene for schizophrenia , 2006, Schizophrenia Research.

[113]  Markus M Nöthen,et al.  Association between a promoter polymorphism in the dopamine D2 receptor gene and schizophrenia , 1999, Schizophrenia Research.

[114]  S H Snyder,et al.  Novel neurotransmitters and their neuropsychiatric relevance. , 2000, The American journal of psychiatry.

[115]  S. Mosolov,et al.  Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial , 2007, Nature Medicine.

[116]  Tyrone D. Cannon,et al.  Association of DISC 1 / TRAX Haplotypes With Schizophrenia , Reduced Prefrontal Gray Matter , and Impaired Short-and Long-term Memory , 2005 .

[117]  Pablo V Gejman,et al.  Genomewide linkage scan of 409 European-ancestry and African American families with schizophrenia: suggestive evidence of linkage at 8p23.3-p21.2 and 11p13.1-q14.1 in the combined sample. , 2006, American journal of human genetics.

[118]  J. Aldenhoff,et al.  Improvement of cognitive functions in chronic schizophrenic patients by recombinant human erythropoietin , 2007, Molecular Psychiatry.

[119]  Stefan Arnborg,et al.  Potential genetic variants in schizophrenia: A Bayesian analysis , 2007, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

[120]  R James,et al.  Disrupted in Schizophrenia 1 (DISC1) is a multicompartmentalized protein that predominantly localizes to mitochondria , 2004, Molecular and Cellular Neuroscience.

[121]  Paul J. Harrison,et al.  Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence , 2005, Molecular Psychiatry.

[122]  Yue-Cune Chang,et al.  Dopamine D3 Receptor Ser9Gly Polymorphism and Risperidone Response , 2005, Journal of clinical psychopharmacology.

[123]  Lin He,et al.  Meta-analysis shows strong positive association of the neuregulin 1 (NRG1) gene with schizophrenia. , 2006, Human molecular genetics.

[124]  C. Austin,et al.  Expression of disrupted-in-schizophrenia-1, a schizophrenia-associated gene, is prominent in the mouse hippocampus throughout brain development , 2004, Neuroscience.

[125]  Y. Fukumaki,et al.  Positive associations of polymorphisms in the metabotropic glutamate receptor type 3 gene (GRM3) with schizophrenia , 2003, Psychiatric genetics.

[126]  B. Hemmings,et al.  Ten years of protein kinase B signalling: a hard Akt to follow. , 2001, Trends in biochemical sciences.

[127]  S. Cichon,et al.  Genotype-phenotype studies in bipolar disorder showing association between the DAOA/G30 locus and persecutory delusions: a first step toward a molecular genetic classification of psychiatric phenotypes. , 2005, The American journal of psychiatry.

[128]  A. Meyer-Lindenberg,et al.  Variation in DISC1 affects hippocampal structure and function and increases risk for schizophrenia. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[129]  Lin He,et al.  Association study between the NMDA receptor 2B subunit gene (GRIN2B) and schizophrenia: A HuGE review and meta-analysis , 2007, Genetics in Medicine.

[130]  H. Yamasue,et al.  No association between the metabotropic glutamate receptor type 3 gene (GRM3) and schizophrenia in a Japanese population , 2006, Schizophrenia Research.

[131]  S Purcell,et al.  Genetic investigation of chromosome 5q GABAA receptor subunit genes in schizophrenia , 2005, Molecular Psychiatry.

[132]  Christopher A. Ross,et al.  A schizophrenia-associated mutation of DISC1 perturbs cerebral cortex development , 2005, Nature Cell Biology.

[133]  X. Zhang,et al.  Elevated interleukin-2, interleukin-6 and interleukin-8 serum levels in neuroleptic-free schizophrenia: association with psychopathology , 2002, Schizophrenia Research.

[134]  J. Lieberman,et al.  Brain volume in first-episode schizophrenia , 2006, British Journal of Psychiatry.

[135]  S. Faraone,et al.  Meta-analysis identifies an association between the dopamine D2 receptor gene and schizophrenia , 2003, Molecular Psychiatry.

[136]  B. Devlin,et al.  Novel, Replicated Associations Between Dopamine D3 Receptor Gene Polymorphisms and Schizophrenia in Two Independent Samples , 2006, Biological Psychiatry.

[137]  M. Owen,et al.  No evidence for association between polymorphisms in GRM3 and schizophrenia , 2005, BMC psychiatry.

[138]  T. Arinami,et al.  Failure to confirm association between AKT1 haplotype and schizophrenia in a Japanese case–control population , 2004, Molecular Psychiatry.

[139]  W. Muir,et al.  Mutational screening and association study of glutamate decarboxylase 1 as a candidate susceptibility gene for bipolar affective disorder and schizophrenia , 2005, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[140]  R. Panizzutti,et al.  Serine Racemase Modulates Intracellular D-Serine Levels through an α,β-Elimination Activity* , 2005, Journal of Biological Chemistry.

[141]  Tyrone D. Cannon,et al.  Association of DISC1/TRAX haplotypes with schizophrenia, reduced prefrontal gray matter, and impaired short- and long-term memory. , 2005, Archives of general psychiatry.

[142]  尾關 祐二 Disrupted-in-Schizophrenia-1 (DISC-1) : mutant truncation prevents binding to NudE-like (NUDEL) and inhibits neurite outgrowth , 2004 .

[143]  S. Tsai,et al.  Family-based association study between G72/G30 genetic polymorphism and schizophrenia , 2006, Neuroreport.

[144]  W. Maier,et al.  Further Evidence for Association of Variants in the AKT1 Gene with Schizophrenia in a Sample of European Sib-Pair Families , 2005, Biological Psychiatry.

[145]  K. Kanyas,et al.  Linkage disequlibrium in the DTNBP1 (dysbindin) gene region and on chromosome 1p36 among psychotic patients from a genetic isolate in Israel: Findings from identity by descent haplotype sharing analysis , 2004, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[146]  David C Glahn,et al.  Spatial working memory as an endophenotype for schizophrenia , 2003, Biological Psychiatry.

[147]  M. Ikeda,et al.  Association of AKT1 with schizophrenia confirmed in a Japanese population , 2004, Biological Psychiatry.

[148]  R. Roberts Schizophrenia in translation: disrupted in schizophrenia (DISC1): integrating clinical and basic findings. , 2006, Schizophrenia bulletin.

[149]  Anat Levit,et al.  A complete genetic association scan of the 22q11 deletion region and functional evidence reveal an association between DGCR2 and schizophrenia , 2006, Human Genetics.

[150]  D. Weinberger,et al.  Schizophrenia as a developmental disorder of the cerebral cortex , 1998, Current Opinion in Neurobiology.

[151]  A. Bellon New genes associated with schizophrenia in neurite formation: a review of cell culture experiments , 2007, Molecular Psychiatry.

[152]  R. Yolken,et al.  Association study of IL10, IL1β, and IL1RN and schizophrenia using tag SNPs from a comprehensive database: Suggestive association with rs16944 at IL1β , 2006, Schizophrenia Research.

[153]  M. Tsuang,et al.  Meta-analysis reveals no association of the Val66Met polymorphism of brain-derived neurotrophic factor with either schizophrenia or bipolar disorder , 2007, Psychiatric genetics.

[154]  K. Bechter [The mild encephalitis-hypothesis--new findings and studies]. , 2004, Psychiatrische Praxis.

[155]  Stephan Eliez,et al.  COMT genotype predicts longitudinal cognitive decline and psychosis in 22q11.2 deletion syndrome , 2005, Nature Neuroscience.

[156]  Michael C O'Donovan,et al.  Support for RGS4 as a susceptibility gene for schizophrenia , 2004, Biological Psychiatry.

[157]  G. He,et al.  A case-control study of the relationship between the metabotropic glutamate receptor 3 gene and schizophrenia in the Chinese population , 2005, Schizophrenia Research.

[158]  J. Hallmayer,et al.  Getting our AKT together in schizophrenia? , 2004, Nature Genetics.

[159]  Toshiyasu Suzuki,et al.  Acute treatment with morphine augments the expression of serine racemase and D-amino acid oxidase mRNAs in rat brain. , 2005, European journal of pharmacology.

[160]  R. Straub,et al.  Effect of metabotropic glutamate receptor 3 genotype on N-acetylaspartate measures in the dorsolateral prefrontal cortex. , 2006, The American journal of psychiatry.

[161]  Elias Zintzaras,et al.  Brain-derived neurotrophic factor gene polymorphisms and schizophrenia: a meta-analysis , 2007, Psychiatric genetics.

[162]  N. Brandon,et al.  Inhibition of NUDEL (nuclear distribution element-like)-oligopeptidase activity by disrupted-in-schizophrenia 1. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[163]  M. Talkowski,et al.  Association and linkage analysis of RGS4 polymorphisms with schizophrenia and bipolar disorder in Brazil , 2004, Genes, brain, and behavior.

[164]  Daniel C. Javitt,et al.  D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia , 2005, Biological Psychiatry.

[165]  M. Egan,et al.  Neuregulin1-induced cell migration is impaired in schizophrenia: association with neuregulin1 and catechol-o-methyltransferase gene polymorphisms , 2007, Molecular Psychiatry.

[166]  Chih-Chiang Chiu,et al.  Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study. , 2005, Archives of general psychiatry.

[167]  P. Tonali,et al.  Chronic amphetamine treatment reduces NGF and BDNF in the rat brain , 2007, European Neuropsychopharmacology.

[168]  P. Greengard,et al.  Diverse Psychotomimetics Act Through a Common Signaling Pathway , 2003, Science.

[169]  R. Tavcar,et al.  Increased Th1 and Th2 immune reactivity with relative Th2 dominance in patients with acute exacerbation of schizophrenia. , 2005, Croatian medical journal.

[170]  Ivan Nikolov,et al.  Strong evidence for association between the dystrobrevin binding protein 1 gene (DTNBP1) and schizophrenia in 488 parent-offspring trios from Bulgaria , 2004, Biological Psychiatry.

[171]  Tao Li,et al.  The genetics of schizophrenia: glutamate not dopamine? , 2003, European journal of pharmacology.

[172]  J. Tiihonen,et al.  Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis , 2005, Schizophrenia Research.

[173]  G. Reynolds,et al.  Pharmacogenetics of treatment in first-episode schizophrenia: D3 and 5-HT2C receptor polymorphisms separately associate with positive and negative symptom response , 2005, European Neuropsychopharmacology.

[174]  R. Straub,et al.  Genetic variation in the 6p22.3 gene DTNBP1, the human ortholog of the mouse dysbindin gene, is associated with schizophrenia. , 2002, American journal of human genetics.

[175]  Richard Coppola,et al.  The G72/G30 Gene Complex and Cognitive Abnormalities in Schizophrenia , 2006, Neuropsychopharmacology.

[176]  R. Straub,et al.  Significant correlation in linkage signals from genome-wide scans of schizophrenia and schizotypy , 2007, Molecular Psychiatry.

[177]  B. Kirkpatrick,et al.  DISC1 immunoreactivity at the light and ultrastructural level in the human neocortex , 2006, The Journal of comparative neurology.

[178]  Naoshi Kaneko,et al.  Genomewide high-density SNP linkage analysis of 236 Japanese families supports the existence of schizophrenia susceptibility loci on chromosomes 1p, 14q, and 20p. , 2005, American journal of human genetics.

[179]  H. Beckmann,et al.  Gross and Histological Criteria for Developmental Disorders in Brains of Schizophrenics , 1989, Journal of the Royal Society of Medicine.

[180]  M. Berk,et al.  Serum levels of brain-derived neurotrophic factor in patients with schizophrenia and bipolar disorder , 2007, Neuroscience Letters.

[181]  H. Gurling,et al.  Fine Mapping by Genetic Association Implicates the Chromosome 1q23.3 Gene UHMK1, Encoding a Serine/Threonine Protein Kinase, as a Novel Schizophrenia Susceptibility Gene , 2007, Biological Psychiatry.

[182]  Zhen Yan,et al.  Regulation of NMDA Receptors by Neuregulin Signaling in Prefrontal Cortex , 2005, The Journal of Neuroscience.

[183]  B. Devlin,et al.  Association and linkage analyses of RGS4 polymorphisms in schizophrenia. , 2002, Human molecular genetics.

[184]  T. Arinami,et al.  A functional polymorphism in the promoter region of the dopamine D2 receptor gene is associated with schizophrenia. , 1997, Human molecular genetics.

[185]  D. Grayson,et al.  DNA Methyltransferase Inhibitors Coordinately Induce Expression of the Human Reelin and Glutamic Acid Decarboxylase 67 Genes , 2007, Molecular Pharmacology.

[186]  E. G. Jones,et al.  Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics. , 1995, Archives of general psychiatry.

[187]  R. Konno,et al.  Exaggerated responses to chronic nociceptive stimuli and enhancement of N-methyl-d-aspartate receptor-mediated synaptic transmission in mutant mice lacking d-amino-acid oxidase , 2001, Neuroscience Letters.

[188]  A. Sawa,et al.  Disrupted‐in‐Schizophrenia‐1 (DISC1) , 2006, Annals of the New York Academy of Sciences.

[189]  V. Arolt,et al.  The Influence of Typical and Atypical Neuroleptic Drugs in the Production of Interleukin-2 and Interferon-Gamma in vitro , 2003, Neuropsychobiology.

[190]  Lin He,et al.  No significant association between the genetic polymorphisms in the GSK-3 beta gene and schizophrenia in the Chinese population. , 2008, Journal of psychiatric research.

[191]  P. Carvey,et al.  Dopamine D3 Receptors , 2012 .

[192]  H. Shiraishi,et al.  Novel variants in the promoter region of the CREB gene in schizophrenic patients , 1999, Journal of Human Genetics.

[193]  M. Matsushita,et al.  A Genetic Variant of the Serine Racemase Gene Is Associated with Schizophrenia , 2007, Biological Psychiatry.

[194]  Birgit Funke,et al.  Association of the DTNBP1 locus with schizophrenia in a U.S. population. , 2004, American journal of human genetics.

[195]  P. Visscher,et al.  Genome scan meta-analysis of schizophrenia and bipolar disorder, part III: Bipolar disorder. , 2003, American journal of human genetics.

[196]  N. Craddock,et al.  Genes for schizophrenia and bipolar disorder? Implications for psychiatric nosology. , 2005, Schizophrenia bulletin.

[197]  W. Maier,et al.  Fortschritte in der neurobiologischen Erforschung der Schizophrenie , 2006, Der Nervenarzt.

[198]  M. Harte,et al.  The neuronal pathology of schizophrenia: molecules and mechanisms. , 2007, Biochemical Society transactions.

[199]  神谷 篤 A schizophrenia-associated mutation of DISC1 perturbs cerebral cortex development , 2006 .

[200]  Daniel R Weinberger,et al.  Expression of DISC1 binding partners is reduced in schizophrenia and associated with DISC1 SNPs. , 2006, Human molecular genetics.

[201]  R. Kahn,et al.  Reviewing the role of the genes G72 and DAAO in glutamate neurotransmission in schizophrenia , 2007, European Neuropsychopharmacology.

[202]  L. Almasy,et al.  A Novel Missense Mutation in the Transmembrane Domain of Neuregulin 1 is Associated with Schizophrenia , 2006, Biological Psychiatry.

[203]  Heather C Whalley,et al.  A neuregulin 1 variant associated with abnormal cortical function and psychotic symptoms , 2006, Nature Neuroscience.

[204]  M. Farquhar,et al.  The regulator of G protein signaling family. , 2000, Annual review of pharmacology and toxicology.